CDC website changed to contradict scientific conclusion that vaccines don’t cause autism

The CDC updated its vaccine-safety webpage to say the statement "Vaccines do not cause autism" is not an evidence-based claim, overturning the agency’s long-standing position and triggering sharp criticism from public-health and autism experts who note decades of studies show no link. The edit — made amid an HHS-led review of autism causes after Robert F. Kennedy Jr.’s appointment as HHS secretary — was reportedly unknown to many CDC scientists, cites no new research, and has prompted concerns about governance, institutional credibility and potential impacts on public confidence in vaccines and broader regulatory trust.

Analysis

The CDC updated its vaccine-safety webpage on Wednesday to state that the phrase "Vaccines do not cause autism" "is not an evidence-based claim," a change the article says cites no new research and was immediately criticized by public-health groups. The edit occurred amid an HHS-led review of autism causes after Robert F. Kennedy Jr.’s appointment as HHS secretary; HHS spokesman Andrew Nixon said the department is launching a comprehensive assessment and updating CDC content. Several former CDC officials — including Dr. Debra Houry and Dr. Daniel Jernigan, who resigned in August — and advocacy groups like the Autism Science Foundation and the American Academy of Pediatrics described the change as ideologically driven and damaging to institutional credibility. The page still displays the headline "Vaccines do not cause autism" but with an asterisk retained under an agreement with Senate HELP chair Bill Cassidy, highlighting heightened governance and regulatory uncertainty; sentiment metrics provided show a strongly negative public tone (sentiment_score -0.62) but only modest direct market impact (market_impact_score 0.3).

Key Decisions for Investors

• Monitor HHS and CDC communications daily for follow-up statements, formal studies cited, or reversals that could materially change regulatory risk around vaccine policy
• Avoid initiating large directional positions in vaccine- or public-health–exposed equities until the HHS review publishes evidence or policy guidance, and consider using hedges (options or pairs) to protect existing exposure
• Watch for operational fallout such as additional senior scientist departures, congressional scrutiny, or litigation risk that would increase regulatory uncertainty for healthcare and biotech names
• Reassess portfolio stress scenarios for reputational contagion affecting vaccine uptake and short-term demand; if exposure is meaningful, shift to more defensive healthcare or increase cash/hedges until clarity is restored